MannKind Corporation (NASDAQ: MNKD)
MannKind has had a tough time in the market. However, if you’re a bull, I’m here to tell you that all is not lost! The reality is that MNKD is a great company that’s been dealt a big blow by Goldman Sachs. Nonetheless, their product is proving to be superior, and that definitely has value. So, today we’ll chat about Afrezza and why it’s so valuable. We’ll also take a look at the stock and talk about why it’s presenting buying opportunities for investors looking for big gains over the long run.
To Understand MNKD You Have To Understand Afrezza
MannKind is one of the most hotly debated stocks in biotech today; and for good reason. There are several misconceptions about the company’s core product. One of which was caused by Goldman Sachs. Here are the misconceptions rolling around, and the truth behind the matter…
- Afrezza Had A Poor Launch – In the recent Goldman Sachs downgrade, the analyst mentioned that the launch of Afrezza was unfavorable; that sales just weren’t meeting expectations. However, it’s important to remember that the downgrade came just 3 weeks after Afrezza first hit the market. In my personal opinion, 3 weeks isn’t enough time to gauge sales.
- Afrezza Isn’t Superior To Other Insulin – This is a big one for me; only because I have family with diabetes and I know what severe spikes in blood sugar can bring. The reality is that Afrezza patients experience less spikes. They aren’t woken up by blood sugar issues anymore!
- Physicians Need To Get Involved – This is the case, but if you don’t think physicians are getting involved, you’re horribly mistaken. The truth is that in the past month, we’ve seen more than one analyst upgrade MNKD or increase the target price. Why? Because of physician feedback. The bottom line is that physicians seem to love Afrezza.
One More Key Detail MNKD Investors Seem To Be Missing Out On
While Afrezza is being used by several patients at the moment, it hasn’t even reached its official launch! The bottom line is that there is far more good news coming for MNKD from Afrezza than most realize. The launch trajectory for the inhaled insulin is over the next 12 to 18 months; we’ve just reached the tip of the ice burg here. There are also issues with label expansion that are being worked out, and a push to offer Afrezza in the European Union.
Where MannKind Stock Is Headed Long Term
I can understand that if you look at only a few weeks of sales before the official launch, why it would look like Afrezza isn’t going well. However, we haven’t even begun to see this thing move through the market. When it does, I think the bears are going to be disappointed with themselves. Overall, I’m expecting to see massive long term gains from MNKD!
What Do You Think?
Where do you think MNKD is headed and why? Let us know in the comments below!